Transferrin surface-modified PLGA nanoparticles-mediated delivery of a proteasome inhibitor to human pancreatic cancer cells

Journal of Biomedical Materials Research - Part A

Volumn 103, Issue 4, 2015, Pages 1476-1484

  Frasco, Manuela F ^a   Almeida, Gabriela M ^a   Santos Silva, Filipe ^a,b,c   Do Carmo Pereira, Maria ^a   Coelho, Manuel A N ^a  

^a UNIVERSITY OF PORTO   (Portugal)

^b University of Porto   (Portugal)

^c UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

Author keywords

Bortezomib; Pancreatic cancer; Plga nanoparticles; Poloxamers; Transferrin

Indexed keywords

COPOLYMERS; CYTOLOGY; CYTOTOXICITY; DISEASES; DRUG DELIVERY; DRUG PRODUCTS; MOBILE SECURITY; NANOPARTICLES;

BORTEZOMIB; PANCREATIC CANCERS; PLGA NANOPARTICLES; POLOXAMERS; TRANSFERRIN;

CELLS;

BORTEZOMIB; NANOCARRIER; NANOPARTICLE; POLOXAMER; POLYGLACTIN; TRANSFERRIN; BORONIC ACID DERIVATIVE; LACTIC ACID; POLYGLYCOLIC ACID; POLYLACTIC ACID-POLYGLYCOLIC ACID COPOLYMER; PROTEASOME INHIBITOR; PYRAZINE DERIVATIVE; TELOMERASE;

ARTICLE; CELL GROWTH; CELL PROLIFERATION; CONTROLLED STUDY; CYTOTOXICITY; DRUG DELIVERY SYSTEM; DRUG STABILITY; HUMAN; HUMAN CELL; IN VITRO STUDY; INTERNALIZATION; PANCREATIC CANCER CELL LINE; PARTICLE SIZE; PHYSICAL CHEMISTRY; SURFACE CHARGE; SUSTAINED DRUG RELEASE; CELL DEATH; CHEMISTRY; DRUG EFFECTS; ENDOCYTOSIS; INFRARED SPECTROSCOPY; METABOLISM; PANCREAS TUMOR; PATHOLOGY; TUMOR CELL LINE; ULTRASTRUCTURE;

BORONIC ACIDS; CELL DEATH; CELL LINE, TUMOR; ENDOCYTOSIS; HUMANS; LACTIC ACID; NANOPARTICLES; PANCREATIC NEOPLASMS; POLYGLYCOLIC ACID; PROTEASOME INHIBITORS; PYRAZINES; SPECTROSCOPY, FOURIER TRANSFORM INFRARED; TELOMERASE; TRANSFERRIN;

EID: 84923600004     PISSN: 15493296     EISSN: 15524965     Source Type: Journal    
DOI: 10.1002/jbm.a.35286     Document Type: Article

References (43)

1. McCarroll J, Teo J, Boyer C, Goldstein D, Kavallaris M, Phillips PA. Potential applications of nanotechnology for the diagnosis and treatment of pancreatic cancer. Front Physiol 2014;5:2.
2. Dong X, Mumper RJ. Nanomedicinal strategies to treat multidrugresistant tumors: Current progress. Nanomedicine 2010;5:597-615.
3. Zhang X-Q, Xu X, Bertrand N, Pridgen E, Swami A, Farokhzad OC. Interactions of nanomaterials and biological systems: Implications to personalized nanomedicine. Adv Drug Deliv Rev 2012;64:1363-1384.
4. Makadia HK, Siegel SJ. Poly lactic-co-glycolic acid (PLGA) as biodegradable controlled drug delivery carrier. Polymers 2011;3: 1377-1397.
5. Danhier F, Ansorena E, Silva JM, Coco R, Le Breton A, Préat V. PLGA-based nanoparticles: An overview of biomedical applications. J Control Release 2012;161:505-522.
6. Danhier F, Feron O, Préat V. To exploit the tumor microenvironment: Passive and active tumor targeting of nanocarriers for anticancer drug delivery. J Control Release 2010;148:135-146.
7. Wang Y, Guo M, Lu Y, Ding L-Y, Ron W-T, Liu Y-Q, Song F-F, Yu S-Q. Alpha-tocopheryl polyethylene glycol succinate-emulsified poly(lactic-co-glycolic acid) nanoparticles for reversal of multidrug resistance in vitro. Nanotechnology 2012;23:495103.
8. Szakács G, Paterson JK, Ludwig JA, Booth-Genthe C, Gottesman MM. Targeting multidrug resistance in cancer. Nat Rev Drug Discov 2006;5:219-234.
9. Kabanov AV, Batrakova EV, Alakhov VYu. PluronicVR block copolymers for overcoming drug resistance in cancer. Adv Drug Deliv Rev 2002;54:759-779.
10. Bertrand N, Wu J, Xu X, Kamaly N, Farokhzad OC. Cancer nanotechnology: The impact of passive and active targeting in the era of modern cancer biology. Adv Drug Deliv Rev 2014;66:2-25.
11. Qian ZM, Li H, Sun H, Ho K. Targeted drug delivery via the transferrin receptor-mediated endocytosis pathway. Pharmacol Rev 2002;54:561-587.
12. Daniels TR, Bernabeu E, Rodríguez JA, Patel S, Kozman M, Chiappetta DA, Holler E, Ljubimova JY, Helguera G, Penichet ML. The transferrin receptor and the targeted delivery of therapeutic agents against cancer. Biochim Biophys Acta 2012;1820:291-317.
13. Schmidt M, Finley D. Regulation of proteasome activity in health and disease. Biochim Biophys Acta 2014;1843:13-25.
14. Adams J. The proteasome: Structure, function, and role in the cell. Cancer Treat Rev 2003;29:3-9.
15. Wu WKK, Cho CH, Lee CW, Wu K, Fan D, Yu J, Sung JJY. Proteasome inhibition: A new therapeutic strategy to cancer treatment. Cancer Lett 2010;293:15-22.
16. Adams J. The proteasome: A suitable antineoplastic target. Nat Rev Cancer 2004;4:349-360.
17. Lee KM, Yasuda H, Hollingsworth MA, Ouellette MM. Notch2-positive progenitors with the intrinsic ability to give rise to pancreatic ductal cells. Lab Invest 2005;85:1003-1012.
18. Iwamura T, Caffrey TC, Kitamura N, Yamanari H, Setoguchi T, Hollingsworth MA. P-selectin expression in a metastatic pancreatic tumor cell line (SUIT-2). Cancer Res 1997;57:1206-1212.
19. Panyam J, Zhou W-Z, Prabha S, Sahoo SK, Labhasetwar V. Rapid endo-lysosomal escape of poly(DL-lactide-co-glycolide) nanoparticles: Implications for drug and gene delivery. FASEB J 2002;16: 1217-1226.
20. Vichai V, Kirtikara K. Sulforhodamine B colorimetric assay for cytotoxicity screening. Nat Protoc 2006;1:1112-1116.
21. Tobío M, Nolley J, Guo Y, McIver J, Alonso MJ. A novel system based on a Poloxamer/PLGA blend as a tetanus toxoid delivery vehicle. Pharm Res 1999;16:682-688.
22. Batrakova EV, Kabanov AV. Pluronic block copolymers: Evolution of drug delivery concept from inert nanocarriers to biological response modifiers. J Control Release 2008;130:98-106.
23. Santander-Ortega MJ, Jódar-Reyes AB, Csaba N, Bastos-González D, Ortega-Vinuesa JL. Colloidal stability of Pluronic F68-coated PLGA nanoparticles: A variety of stabilisation mechanisms. J Colloid Interface Sci 2006;302:522-529.
24. Vasita R, Katti DS. Structural and functional characterization of proteins adsorbed on hydrophilized polylactide-co-glycolide microfibers. Int J Nanomedicine 2012;7:61-71.
25. del Pino P, Pelaz B, Zhang Q, Maffre P, Nienhaus GU, Parak WJ. Protein corona formation around nanoparticles-From the past to the future. Mater Horiz 2014;1:301-313.
26. Barth A, Zscherp C. What vibrations tell us about proteins. Q Rev Biophys 2002;35:369-430.
27. Göpferich A. Mechanisms of polymer degradation and erosion. Biomaterials 1996;17:103-114.
28. Versypt ANF, Pack DW, Braatz RD. Mathematical modeling of drug delivery from autocatalytically degradable PLGA microspheres-A review. J Control Release 2013;165:29-37.
29. Mattu C, Pabari RM, Boffito M, Sartori S, Ciardelli G, Ramtoola Z. Comparative evaluation of novel biodegradable nanoparticles for the drug targeting to breast cancer cells. Eur J Pharm Biopharm 2013;85:463-472.
30. Shah SA, Potter MW, McDade TP, Ricciardi R, Perugini RA, Elliott PJ, Adams J, Callery MP. 26S Proteasome inhibition induces apoptosis and limits growth of human pancreatic cancer. J Cell Biochem 2001;82:110-122.
31. Bold RJ, Virudachalam S, McConkey DJ. Chemosensitization of pancreatic cancer by inhibition of the 26S proteasome. J Surg Res 2001;100:11-17.
32. Nawrocki ST, Bruns CJ, Harbison MT, Bold RJ, Gotsch BS, Abbruzzese JL, Elliott P, Adams J, McConkey DJ. Effects of the proteasome inhibitor PS-341 on apoptosis and angiogenesis in orthotopic human pancreatic tumor xenografts. Mol Cancer Ther 2002;1:1243-1253.
33. Nawrocki ST, Sweeney-Gotsch B, Takamori R, McConkey DJ. The proteasome inhibitor bortezomib enhances the activity of docetaxel in orthotopic human pancreatic tumor xenografts. Mol Cancer Ther 2004;3:59-70.
34. Nawrocki ST, Carew JS, Dunner K Jr, Boise LH, Chiao PJ, Huang P, Abbruzzese JL, McConkey DJ. Bortezomib inhibits PKR-like endoplasmic reticulum (ER) kinase and induces apoptosis via ER stress in human pancreatic cancer cells. Cancer Res 2005;65: 11510-11519.
35. Adams J, Palombella VJ, Sausville EA, Johnson J, Destree A, Lazarus DD, Maas J, Pien CS, Prakash S, Elliott PJ. Proteasome inhibitors: A novel class of potent and effective antitumor agents. Cancer Res 1999;59:2615-2622.
36. Mura S, Hillaireau H, Nicolas J, Le Droumaguet B, Gueutin C, Zanna S, Tsapis N, Fattal E. Influence of surface charge on the potential toxicity of PLGA nanoparticles towards Calu-3 cells. Int J Nanomedicine 2011;6:2591-2605.
37. Menon JU, Kona S, Wadajkar AS, Desai F, Vadla A, Nguyen KT. Effects of surfactants on the properties of PLGA nanoparticles. J Biomed Mater Res A 2012;100:1998-2005.
38. Panyam J, Labhasetwar V. Dynamics of endocytosis and exocytosis of poly(D,L-lactide-co-glycolide) nanoparticles in vascular smooth muscle cells. Pharm Res 2003;20:212-220.
39. Sorokin LM, Morgan EH, Yeoh GCT. Transformation-induced changes in transferrin and iron metabolism in myogenic cells. Cancer Res 1989;49:1941-1947.
40. Milani S, Bombelli FB, Pitek AS, Dawson KA, Rädler J. Reversible versus irreversible binding of transferrin to polystyrene nanoparticles: Soft and hard corona. ACS Nano 2012;6:2532-2541.
41. Sempf K, Arrey T, Gelperina S, Schorge T, Meyer B, Karas M, Kreuter J. Adsorption of plasma proteins on uncoated PLGA nanoparticles. Eur J Pharm Biopharm 2013;85:53-60.
42. Choi CHJ, Alabi CA, Webster P, Davis ME. Mechanism of active targeting in solid tumors with transferrin-containing gold nanoparticles. Proc Natl Acad Sci USA 2010;107:1235-1240.
43. Salvati A, Pitek AS, Monopoli MP, Prapainop K, Bombelli FB, Hristov DR, Kelly PM, Åberg C, Mahon E, Dawson KA. Transfer-rin-functionalized nanoparticles lose their targeting capabilities when a biomolecule corona adsorbs on the surface. Nat Nanotechnol 2013;8:137-143.